530 related articles for article (PubMed ID: 16430398)
21. Breast radiation therapy guideline implementation in low- and middle-income countries.
Bese NS; Munshi A; Budrukkar A; Elzawawy A; Perez CA;
Cancer; 2008 Oct; 113(8 Suppl):2305-14. PubMed ID: 18837022
[TBL] [Abstract][Full Text] [Related]
22. Radiotherapy for breast cancer in countries with limited resources: program implementation and evidence-based recommendations.
Bese NS; Kiel K; El-Gueddari Bel-K; Campbell OB; Awuah B; Vikram B;
Breast J; 2006; 12 Suppl 1():S96-102. PubMed ID: 16430403
[TBL] [Abstract][Full Text] [Related]
23. Optimizing the treatment of metastatic breast cancer.
Gralow JR
Breast Cancer Res Treat; 2005; 89 Suppl 1():S9-S15. PubMed ID: 15770536
[TBL] [Abstract][Full Text] [Related]
24. Polychemotherapy for early breast cancer: results from the international adjuvant breast cancer chemotherapy randomized trial.
Adjuvant Breast Cancer Trials Collaborative Group
J Natl Cancer Inst; 2007 Apr; 99(7):506-15. PubMed ID: 17405995
[TBL] [Abstract][Full Text] [Related]
25. [Risk of cardiotoxicity of combination treatment radiotherapy and chemotherapy of locally advanced breast carcinoma stage III].
Bustová I
Klin Onkol; 2009; 22(1):17-21. PubMed ID: 19534435
[TBL] [Abstract][Full Text] [Related]
26. Chemotherapy versus ovarian ablation as adjuvant therapy for breast cancer: impact on health-related quality of life in a randomized trial.
Groenvold M; Fayers PM; Petersen MA; Mouridsen HT
Breast Cancer Res Treat; 2006 Aug; 98(3):275-84. PubMed ID: 16541325
[TBL] [Abstract][Full Text] [Related]
27. Neoadjuvant endocrine therapy in breast cancer.
Beresford MJ; Ravichandran D; Makris A
Cancer Treat Rev; 2007 Feb; 33(1):48-57. PubMed ID: 17134840
[TBL] [Abstract][Full Text] [Related]
28. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391
[TBL] [Abstract][Full Text] [Related]
29. Hormonal therapy for postmenopausal breast cancer: the science of sequencing.
Miller WR; Bartlett JM; Canney P; Verrill M
Breast Cancer Res Treat; 2007 Jun; 103(2):149-60. PubMed ID: 17039263
[TBL] [Abstract][Full Text] [Related]
30. Review of the development of letrozole and its use in advanced breast cancer and in the neoadjuvant setting.
Bhatnagar AS
Breast; 2006 Feb; 15 Suppl 1():S3-13. PubMed ID: 16500235
[TBL] [Abstract][Full Text] [Related]
31. Preoperative (neoadjuvant) systemic treatment of breast cancer.
Kaufmann M; von Minckwitz G; Rody A
Breast; 2005 Dec; 14(6):576-81. PubMed ID: 16199160
[TBL] [Abstract][Full Text] [Related]
32. Adjuvant endocrine treatment of early breast cancer.
Lønning PE
Hematol Oncol Clin North Am; 2007 Apr; 21(2):223-38. PubMed ID: 17512446
[TBL] [Abstract][Full Text] [Related]
33. Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial.
Sverrisdottir A; Nystedt M; Johansson H; Fornander T
Breast Cancer Res Treat; 2009 Oct; 117(3):561-7. PubMed ID: 19153828
[TBL] [Abstract][Full Text] [Related]
34. Mortality impact of less-than-standard therapy in older breast cancer patients.
Yood MU; Owusu C; Buist DS; Geiger AM; Field TS; Thwin SS; Lash TL; Prout MN; Wei F; Quinn VP; Frost FJ; Silliman RA
J Am Coll Surg; 2008 Jan; 206(1):66-75. PubMed ID: 18155570
[TBL] [Abstract][Full Text] [Related]
35. Multidisciplinary therapy of locally far-advanced or inflammatory breast cancer with fixed perioperative sequence of epirubicin, vinorelbine, and Fluorouracil chemotherapy, surgery, and radiotherapy: long-term results.
Ardavanis A; Scorilas A; Tryfonopoulos D; Orphanos G; Missitzis I; Karamouzis M; Chrysochoou M; Sotiropoulou A; Arnogiannaki N; Ioannidis G; Pissakas G; Rigatos G
Oncologist; 2006 Jun; 11(6):563-73. PubMed ID: 16794236
[TBL] [Abstract][Full Text] [Related]
36. Beyond tamoxifen: extended and late extended endocrine therapy in postmenopausal early breast cancer.
Dodwell D; Williamson D
Cancer Treat Rev; 2008 Apr; 34(2):137-44. PubMed ID: 18006236
[TBL] [Abstract][Full Text] [Related]
37. Economic and cost-effectiveness issues in breast cancer treatment.
Hillner BE
Semin Oncol; 1996 Feb; 23(1 Suppl 2):98-104. PubMed ID: 8614853
[TBL] [Abstract][Full Text] [Related]
38. The potential risk of neoadjuvant chemotherapy in breast cancer patients--results from a prospective randomized trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-07).
Taucher S; Steger GG; Jakesz R; Tausch C; Wette V; Schippinger W; Kwasny W; Reiner G; Greil R; Dubsky P; Poestlberger S; Tschmelitsch J; Samonigg H; Gnant M;
Breast Cancer Res Treat; 2008 Nov; 112(2):309-16. PubMed ID: 18080748
[TBL] [Abstract][Full Text] [Related]
39. Towards optimal endocrine therapy for hormone-sensitive breast cancer: initial versus sequential adjuvant aromatase inhibition.
Spicer J; Ellis P
Cancer Lett; 2007 Apr; 248(2):165-74. PubMed ID: 16919870
[TBL] [Abstract][Full Text] [Related]
40. [A randomized controlled study comparing uracil-tegafur (UFT)+tamoxifen (UFT+TAM therapy) with cyclophosphamide+adriamycin+5-fluorouracil (CAF therapy) for women with stage I , II, or IIIa breast cancer with four or more involved nodes in the adjuvant setting].
Inaji H; Sakai K; Oka T; Ozawa K; Saito Y; Senoo T; Taguchi T; Terasawa T; Nakao K; Mori T; Koyama H; Oshima A
Gan To Kagaku Ryoho; 2006 Oct; 33(10):1423-9. PubMed ID: 17033231
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
